Preclinical target validation using patient-derived cells.
The Structural Genomics Consortium (SGC) and its clinical, industry and disease-foundation partners are launching open-source preclinical translational medicine studies.
Structural Genomics Consortium, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada.
Aled M
AM
Edwards
1] Structural Genomics Consortium, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada. [2] Princess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto, Ontario M5G 1L7, Canada.
Cheryl H
CH
Arrowsmith
Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7LD, UK.
Chas
C
Bountra
Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, USA.
Mark E
ME
Bunnage
Kennedy Institute of Rheumatology, University of Oxford, Roosevelt Drive, Headington, Oxford, OX3 7FY, UK.
Marc
M
Feldmann
Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK.
Julian C
JC
Knight
Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.
Dhavalkumar D
DD
Patel
Structural Genomics Consortium, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada.
Panagiotis
P
Prinos
Division of Neurosurgery, Program in Developmental and Stem Cell Biology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8.
Michael D
MD
Taylor
Structural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, 171 76 Stockholm, Sweden.
Michael
M
Sundström
D002460:Cell Line; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D010361:Patients; D061251:Primary Cell Culture; D055818:Public-Private Sector Partnerships; D057170:Translational Research, Biomedical